Shield Therapeutics’ (STX) “Buy” Rating Reaffirmed at Peel Hunt

Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research note issued to investors on Friday morning, Marketbeat.com reports. The brokerage currently has a GBX 15 target price on the stock.

Shield Therapeutics Stock Up 2.6%

Shares of STX traded up GBX 0.18 during midday trading on Friday, hitting GBX 6.93. The stock had a trading volume of 2,286,293 shares, compared to its average volume of 2,729,643. The company has a 50 day simple moving average of GBX 7.54 and a two-hundred day simple moving average of GBX 4.94. Shield Therapeutics has a twelve month low of GBX 2.10 and a twelve month high of GBX 9.10. The firm has a market cap of £73.53 million, a price-to-earnings ratio of -3.46 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.